NCT02362594 2026-03-05
MK-3475-054
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
74 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT05907122 2026-02-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT05549297 2026-02-25
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd
Phase 3 Recruiting
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT06246916 2026-02-19
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07015190 2026-02-18
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT03820986 2026-02-09
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06054555 2026-01-12
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen
Phase 3 Active not recruiting
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT04889118 2025-12-23
LEAP-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03567889 2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3 Recruiting
NCT01546571 2025-10-24
MAVIS
Polynoma LLC
Phase 3 Terminated
NCT05665595 2025-10-15
KEYVIBE-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT05933577 2025-09-24
V940-001
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT05155254 2025-08-28
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
IO Biotech
Phase 3 Active not recruiting
NCT04099251 2025-08-27
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02752074 2025-08-24
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Incyte Corporation
Phase 3 Completed
NCT05625399 2025-08-24
RELATIVITY-127
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT05751928 2025-07-08
NEO-MIMAJOR
Biocad
Phase 3 Active not recruiting
NCT06640530 2025-07-08
UNIVERSE
Biocad
Phase 3 Active not recruiting
NCT01844505 2025-05-21
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Bristol-Myers Squibb
Phase 3 Completed
NCT05608291 2025-05-13
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT03551626 2025-04-29
COMBI-APlus
Novartis
Phase 3 Completed
NCT02388906 2025-04-24
CheckMate 238
Bristol-Myers Squibb
Phase 3 Completed
NCT03635983 2025-04-01
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT05732805 2025-02-27
OCTAVA
Biocad
Phase 3 Active not recruiting
NCT03553836 2024-11-29
KEYNOTE-716
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06320353 2024-03-20
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
R-Pharm
Phase 3 Active not recruiting
NCT05270044 2023-11-22
COLUMBUS-AD
Pierre Fabre Medicament
Phase 3 Active not recruiting
NCT05986331 2023-09-21
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Biocad
Phase 3 Unknown
NCT01682083 2023-08-30
COMBI-AD
Novartis
Phase 3 Completed
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT05783882 2023-03-24
FLAT
Biocad
Phase 3 Unknown
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT01721772 2022-07-12
CheckMate 066
Bristol-Myers Squibb
Phase 3 Completed
NCT02714218 2022-06-24
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT01721746 2022-04-19
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb
Phase 3 Completed
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT03068455 2021-09-20
CheckMate 915
Bristol-Myers Squibb
Phase 3 Completed
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT02599402 2021-06-15
CheckMate 401
Bristol-Myers Squibb
Phase 3 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT01584648 2021-02-17
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Novartis
Phase 3 Completed
NCT01280565 2020-11-05
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
AB Science
Phase 3 Terminated